Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Roth E, Bingaman A, Stern S, McKeever R, D'Orazio J, Schlosser SP, Cheng K, Zhao H, Anderson JH. Buprenorphine Induction in Trauma Patients With Opioid Use Disorder - A Single Center Experience? J Surg Res. 2024 Sep; 301:686-695.
-
Santos T, Bergman A, Smith-McLallen A. Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus. JAMA Netw Open. 2024 Apr 01; 7(4):e248519.
-
Mallinson DC, Kuo HD, Kirby RS, Wang Y, Berger LM, Ehrenthal DB. Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018. Prev Med. 2024 Apr; 181:107914.
-
Hagan L, David EM, Horton AR, Marx JO. Effects of Midazolam/Dexmedetomidine with Buprenorphine or Extended-release Buprenorphine Anesthesia in C57BL/6 Mice. J Am Assoc Lab Anim Sci. 2024 03 01; 63(2):172-181.
-
Stern SJ, D'Orazio JL, Work BD, Calcaterra SL, Thakrar AP. Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal? J Hosp Med. 2024 Apr; 19(4):339-343.
-
Prince E, Loeser P, Early M, Carroll CP, Lanzkron S, Pecker LH. "Buprenorphine, It Works so Differently": Adults with Sickle Cell Disease Describe Transitioning to Buprenorphine for Treatment of Chronic Pain. J Pain. 2024 Mar; 25(3):632-641.
-
Ahmed S, Faruqui Z, Poddar K, Bhivandkar S, Suzuki J. Low-dose buprenorphine initiation in the era of fentanyl and fentanyl analogs: A case series of outpatient inductions. J Opioid Manag. 2023 Sep-Oct; 19(5):455-460.
-
Reed MK, Smith KR, Ciocco F, Hass RW, Cox AL, Kelly EL, Weinstein LC. Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program. Subst Abuse Treat Prev Policy. 2023 Jan 14; 18(1):4.
-
Sugarman A, Vittitow A, Cheng A, Malone M, McDonald R, Pace N, Williams O, Tofighi B, McNeely J, Schatz D, Roberts T, Hey SP, Garrity K, Lindquist K, Lee JD. Opioid Use Disorder Treatments: An Evidence Map. Drug Alcohol Depend. 2022 Dec 01; 241:109657.
-
David MS, Jones J, Lauriello A, Nnake I, Plazas Montana M, Lasko K, Buri-Nagua C, Olagbaju Y, Williams E, Sears M, Salzberg B, Lanzkron SM, Carroll CP. Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization. Am J Hematol. 2022 Nov; 97(11):1435-1442.